FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W777409399> ?p ?o ?g. }

• W777409399 abstract "Abstract Introduction The prevalence of myelofibrosis (MF) is 3.6 to 5.6 cases per 100,000 in the United States. Overall median survival is 3 years and 1.3 years for patients with intermediate-2 and high-risk disease, respectively. The MF PracticE-Based Network ResearCH (ENRiCH) platform is an adaptive, dynamic, data hub designed to accumulate real-world data to identify MF patients, understand their treatment patterns and unmet needs, inform clinical trial design, and conduct research using clinically relevant outcomes. A descriptive analysis of the demographic and clinical characteristics of MF patients from the ENRiCH platform is reported in this study. Methods The ENRiCH platform was developed from patient-level data representing approximately 1 billion US private practitioner medical claims, >1.6 billion pharmacy claims, and electronic medical records from >500,000 cancer patients treated in community oncology practices at 344 locations in 37 states and encompassing approximately 550 treating providers. ENRiCH includes patients with a diagnosis of MF, polycythemia vera (PV), or essential thrombocytopenia (ET), and/or a ruxolitinib prescription between November 1, 2010 and October 31, 2012; patients who received ruxolitinib in a clinical trial were excluded. Results As of March 2013, 6362 MF and 299 ruxolitinib patients were identified. Mean (SD) age was 67.0 (12.6) years for MF patients and 65.8 (15.0) years for the ruxolitinib subgroup, with 45% females. Hematologic comorbidities included myeloid disorders (80% MF; 70% ruxolitinib) and lymphoid disorders (10% MF; 5% ruxolitinib). The most common myeloid disorders were primary MF (47% MF; 29% ruxolitinib), myelodysplastic syndrome (35% MF; 26% ruxolitinib), ET (25% MF; 17% ruxolitinib), and PV (25% MF; 17% ruxolitinib). Common comorbidities of interest that were observed included infectious diseases (35% MF; 35% ruxolitinib), thrombocytopenia (33% MF; 23% ruxolitinib), pulmonary hypertension (7% MF; 7% ruxolitinib), and vitamin D deficiency (7% MF; 8% ruxolitinib). The mean (SD) Charlson comorbidity index (CCI) was 4.36 (2.4) for MF patients and 4.28 (2.4) for the ruxolitinib subgroup. Clinical characteristics and laboratory results among patients with diagnostic or clinical data from the index date forward are shown in the table. The 5 most common concomitant medication groups for ruxolitinib patients were loop diuretics (11%), gout agents (10%), hydrocodone combinations (9%), opioid agonists (9%), and proton pump inhibitors (9%). The top 5 most common medications taken within 180 days prior to new ruxolitinib starts were hydrocodone combinations (21%), antineoplastics (19%), gout agents (18%), glucocorticosteroids (15%), and fluoroquinolones (14%). The predominant [MF (ruxolitinib)] payer types observed were Medicare [48% (37%)], Medicaid [4% (1%)], and commercial insurance [37% (21%)]. Conclusions The observed demographic and clinical characteristics of MF patients are similar to prior MF epidemiological studies (Mehta J et al. Leuk Lymphoma. 2013;Early Online: 1-6), suggesting that the sample of MF ENRiCH patients is reflective of the broader US MF population and will allow for broad-based quantification of unmet needs and treatment outcomes. The addition of more MF patients and longer follow-up data will further enhance the value of this large US real-world MF patient data hub including those on current MF therapies. This study was sponsored by Sanofi. Disclosures: Fonseca: IMS Health - a company that received funds from Sanofi to conduct the study: Employment. Lee:Sanofi: Employment. Wang:Sanofi: Employment, Equity Ownership. Dhawan:Sanofi: Employment. Thompson:Sanofi: Employment. Iqbal:Sanofi: Employment, Equity Ownership. Redmond:IMS Health: Consultancy, Employment." @default.
• W777409399 created "2016-06-24" @default.
• W777409399 creator A5033435340 @default.
• W777409399 creator A5069025117 @default.
• W777409399 creator A5069483554 @default.
• W777409399 creator A5070684364 @default.
• W777409399 creator A5070927851 @default.
• W777409399 creator A5077752564 @default.
• W777409399 creator A5079485616 @default.
• W777409399 creator A5082989514 @default.
• W777409399 date "2013-11-15" @default.
• W777409399 modified "2023-09-26" @default.
• W777409399 title "Characteristics Of Patients Included In The Myelofibrosis Real-World Practice-Based Network Research (ENRiCH) Data Platform" @default.
• W777409399 doi "https://doi.org/10.1182/blood.v122.21.1580.1580" @default.
• W777409399 hasPublicationYear "2013" @default.
• W777409399 type Work @default.
• W777409399 sameAs 777409399 @default.
• W777409399 citedByCount "1" @default.
• W777409399 countsByYear W7774093992023 @default.
• W777409399 crossrefType "journal-article" @default.
• W777409399 hasAuthorship W777409399A5033435340 @default.
• W777409399 hasAuthorship W777409399A5069025117 @default.
• W777409399 hasAuthorship W777409399A5069483554 @default.
• W777409399 hasAuthorship W777409399A5070684364 @default.
• W777409399 hasAuthorship W777409399A5070927851 @default.
• W777409399 hasAuthorship W777409399A5077752564 @default.
• W777409399 hasAuthorship W777409399A5079485616 @default.
• W777409399 hasAuthorship W777409399A5082989514 @default.
• W777409399 hasConcept C104863432 @default.
• W777409399 hasConcept C126322002 @default.
• W777409399 hasConcept C143998085 @default.
• W777409399 hasConcept C2426938 @default.
• W777409399 hasConcept C2776112149 @default.
• W777409399 hasConcept C2780007613 @default.
• W777409399 hasConcept C2780076729 @default.
• W777409399 hasConcept C512399662 @default.
• W777409399 hasConcept C535046627 @default.
• W777409399 hasConcept C71924100 @default.
• W777409399 hasConcept C98274493 @default.
• W777409399 hasConceptScore W777409399C104863432 @default.
• W777409399 hasConceptScore W777409399C126322002 @default.
• W777409399 hasConceptScore W777409399C143998085 @default.
• W777409399 hasConceptScore W777409399C2426938 @default.
• W777409399 hasConceptScore W777409399C2776112149 @default.
• W777409399 hasConceptScore W777409399C2780007613 @default.
• W777409399 hasConceptScore W777409399C2780076729 @default.
• W777409399 hasConceptScore W777409399C512399662 @default.
• W777409399 hasConceptScore W777409399C535046627 @default.
• W777409399 hasConceptScore W777409399C71924100 @default.
• W777409399 hasConceptScore W777409399C98274493 @default.
• W777409399 hasLocation W7774093991 @default.
• W777409399 hasOpenAccess W777409399 @default.
• W777409399 hasPrimaryLocation W7774093991 @default.
• W777409399 hasRelatedWork W1924834505 @default.
• W777409399 hasRelatedWork W1988123751 @default.
• W777409399 hasRelatedWork W2157066112 @default.
• W777409399 hasRelatedWork W2531856938 @default.
• W777409399 hasRelatedWork W2556678968 @default.
• W777409399 hasRelatedWork W2761488148 @default.
• W777409399 hasRelatedWork W2768672347 @default.
• W777409399 hasRelatedWork W2950893837 @default.
• W777409399 hasRelatedWork W2971181441 @default.
• W777409399 hasRelatedWork W2985283333 @default.
• W777409399 hasRelatedWork W2996087467 @default.
• W777409399 hasRelatedWork W3010774459 @default.
• W777409399 hasRelatedWork W3019722770 @default.
• W777409399 hasRelatedWork W3097181513 @default.
• W777409399 hasRelatedWork W3128000097 @default.
• W777409399 hasRelatedWork W3165639147 @default.
• W777409399 hasRelatedWork W3186480219 @default.
• W777409399 hasRelatedWork W3194195834 @default.
• W777409399 hasRelatedWork W3197219040 @default.
• W777409399 hasRelatedWork W72531553 @default.
• W777409399 isParatext "false" @default.
• W777409399 isRetracted "false" @default.
• W777409399 magId "777409399" @default.
• W777409399 workType "article" @default.